C

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
cabozantinib film-coated tablets (Cabozantinib Ipsen) SMC2754	as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. Cabozantinib offers an additional treatment choice in the therapeutic class of protein kinase inhibitors. Another protein kinase inhibitor was accepted for use under the end of life process.	Available in line with national guidance.		
Cabazitaxel (Jevtana®) (735/11)	Hormone refractory metastatic prostate cancer	Not recommended	112	Dec 2011
Cabazitazel (Jevtana®) 735/11	In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostrate cancer previously treated with docetaxel containing regimen. SMC restriction: for use in patients who have received at least 225mg/m2 (three cycles) of docetaxel and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by April 2017	156 159	Sep 2016 Feb 2017

cabotegravir prolonged-release suspension for injection and film-coated tablets (Apretude®) SMC2718	Cabotegravir prolonged-release injection: in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir tablets: in combination with safer sex practices for short term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir tablets may be used as: • oral lead-in to assess tolerability of cabotegravir prior to administration of long acting cabotegravir injection. • oral PrEP for individuals who will miss planned dosing with cabotegravir injection. SMC restriction: Adults and adolescents (weighing at least 35kg) at high risk of sexually acquired HIV who are eligible for PrEP, including oral PrEP, but for whom oral PrEP is not appropriate to meet their HIV prevention needs. Cabotegravir was superior to daily oral tenofovir disoproxil fumarate/emtricitabine in the reduction of incident HIV acquisitions in a phase IIb/III study in men who have sex with men and transgender women (HPTN 083) and in a phase III study in cisgender women (HPTN 084) at high risk of acquiring human immunodeficiency virus (HIV).	Available in line with national guidance.		

cabotegravir 600mg prolonged-release suspension for injection (Vocabria®) SMC2376	in combination with rilpivirine prolonged-release injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class Cabotegravir 600mg prolonged release injection plus rilpivirine 900mg prolonged-release injection every 2-months was non-inferior to cabotegravir 400mg plus rilpivirine 600mg every month in terms of the proportion of patients losing virological suppression in a phase III study. Cabotegravir 400mg prolonged release injection plus rilpivirine 600mg prolonged-release injection was non-inferior to oral antiretroviral therapy.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by December 2021	187	Dec 2021
cabozantinib 20mg, 40mg and 60mg film-coated tablets (Cabometyx®) SMC2386	In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults. Cabozantinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors given in combination with a PD-1 inhibitor for this indication. Medicines within this therapeutic class have been accepted under the end of life process for this indication. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.	Available in line with local guidance for prescribing	187	Dec 2021
Cabozantinib 20mg, 40mg and 60mg tablets (Cabometyx®) SMC2160	As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib	Not available as not recommended for use in NHS Scotland	174	May 2019

Cabozantinib 20mg, 40mg, and 60mg film-coated tablets (Cabometyx®) SMC2136	Advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.	Not available as not recommended for use in NHS Scotland	174	May 2019
Cabozantinib, 20mg, 40mg, and 60mg film-coated tablets (Cabometyx®) SMC2095	Advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk. In a phase II study, in treatment-naïve adults with advanced RCC with intermediate or poor risk as defined by the IMDC risk group categories, cabozantinib was superior to another tyrosine kinase inhibitor for progression free survival.	Not available as not recommended for use in NHS Scotland	172	Dec 2018
Cabozantinib, 20mg, 40mg and 60mg film-coated tablets (Cabometyx®) SMC No. (1234/17)	For the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Available in line with national guidance	162	Aug 2017
Cabozantinib (Cometriq®) (1022/15)	For the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.	Not recommended	146	Mar 2015
Cabozantinib film-coated tablets (Cabometyx®) SMC2590	As monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.	Not available as not recommended for use in NHS Scotland	196 – Awaiting publication	April - 197
Caffeine base 5mg/ml solution for injection (550/09)	Apnoea of prematurity	HOSPITAL ONLY	89	May 2009
Caffeine citrate (Peyona®) (814/12)	Primary apnoea of premature newborns	HOSPITAL ONLY (Neonatal Intensive Care)	130 121	Sep/Oct 2013 Nov 2012
Calcipotriol 50micrograms/g and betamethasone 0.5g/g cutaneous foam (Enstilar®) (1182/16)	Topical treatment of psoriasis vulgaris in adults.	Available in line with National Guidance Formulary - Green traffic light	157	Nov 2016

Calcipotriol/betamethasone (Xamiol®) (559/09)	Scalp psoriasis	Discontinued	92	Aug/Sep 2009
Calcipotriol/betamethasone (Dovobet®)	Psoriasis		60 55	2006 2002
Calcitriol ointment (Silkis®)	Mild to moderate plaque psoriasis in adults		26	2003
Calcium acetate (Osvaren®) (693/11)	Hyperphosphataemia	Not recommended	105	April/May 2011
Calcium acetate (Phoslo®) (601/10)	Hyperphosphataemia in patients with advanced renal failure on dialysis	Discontinued	106 95	May/June 2011 Feb/Mar 2010
Calcium carbonate(Vitamin D3®) (718/11)	Calcium and vitamin D deficiency	Not recommended in Tayside	109	Sep 2011
Calcium/colecalciferol (Calfovit D3®)	Ca/Vit D deficiency in the elderly		36 32	2003
Calcium polystyrene sulphonate (Sorbisterit®) (890/13)	Treatment of hyperkalaemia, in patients with acute and chronic renal insufficiency, including patients undergoing dialysis treatment.	Discontinued	129 151	Aug/Sep 2013 Sep/Oct 2015
Caplacizumab 10mg powder and solvent for solution for injection (Cablivi®) SMC2266				
Camellia sinensis (green tea) leaf extract 10% ointment (Catephen®) SMC 1133/16	Cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years. SMC Restriction: for use in patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.	Available in line with local guidance for prescribing	155	June 2016

Canakinumab 150mg powder for solution for injection (Ilaris®) SMC No. (1268/17)	Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: • tumour necrosis factor receptor associated periodic syndrome • hyperimmunoglobulin D syndrome/mevalonate kinase deficiency • Familial Mediterranean Fever	Not available as not recommended for use in NHS Scotland	163	Sep 2017
Canagliflozin plus metformin (Vokanamet®) (1019/14)	Type 2 diabetes mellitus	Formulary	145	Feb 2015
Canagliflozin (Invokana®) (963/14)	Type 2 diabetes mellitus	Formulary	139	Jun/Jul 2014
Canakinumab 150mg powder for solution for injection (Ilaris®) SMC 1210/16	Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate	Not available as not recommended for use in NHS Scotland	158	Dec 2016
Canakinumab (Ilaris®) (926/13)	SJIA	Not recommended	132	Nov/Dec 2013
Canakinumab (Ilaris®) (882/13)	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS	Not recommended	128	Jun/Jul 2013
Canakinumab (Ilaris®) (883/13)	Gouty arthritis attacks	Not recommended	128	Jun/Jul 2013
Canakinumab (Ilaris®) (658/11)	Cryopyrin-Associated Periodic Syndromes (CAPS) in adults	Not recommended	100	Oct/Nov 2010
Candesartan (Amias®)	Heart failure	Formulary	50	2005
Cangrelor (Kengraxel®) (1070/15)	Co-administered with acetylsalicylic acid for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.	Not recommended	149	Jun/Jul 2015

cannabidiol 100mg/mL oral solution (Epidyolex®) SMC2402	for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. Cannabidiol reduced TSC-associated seizure frequency compared with placebo in one randomised, double-blind, phase III study in patients with TSC-associated epilepsy that was inadequately controlled by other anti-epileptic drugs.	PAEDS - Not routinely available as local clinical experts do not wish to add the medicine to the fomrulary at this time or there is a local preference for alternative medicines.	188	April 2022
Cannabidiol 100mg/ml oral solution (Epidyolex®) SMC2263	For use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome, in conjunction with clobazam, for patients 2 years of age and older. In two phase III, placebo-controlled studies cannabidiol reduced drop seizure frequency in the clobazam-treated subgroup of children and adults (aged 2 to 55 years) with Lennox-Gastaut syndrome that was inadequately controlled by other anti-epileptic drugs.	Paediatrics: Available in line with national guidance ADULTS: Available in line with national guidance	181	November 2020
Cannabidiol 100mg/ml oral solution (Epidyolex®) SMC2262	For use as adjunctive therapy of seizures associated with Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. In two phase III, placebo-controlled studies cannabidiol reduced convulsive seizure frequency in the clobazam-treated subgroup of children (aged 2 to 18 years) with Dravet syndrome that was inadequately controlled by other anti-epileptic drugs.	Paediatrics: Available in line with national guidance ADULTS: Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	181	November 2020
Cannabinoid spray (Sativex®) (703/11)	Moderate to severe spasticity	Not recommended	105	Apr/May 2011
Capecitabine (Xeloda®) (507/08)	Metastatic colorectal cancer	HOSPITAL ONLY	83	Oct 2008

Capecitabine (Xeloda®) (401/07)	Advanced gastric cancer	HOSPITAL ONLY	72	Sep 2007
Capecitabine (Xeloda®) (716/11)	Adjuvant treatment of Dukes' C colon cancer	HOSPITAL ONLY (Oncology)	109 53	Sep 2011 2005
Capecitabine (Xeloda®)	Advanced metastatic breast cancer		25	2003
Caplacizumab 10mg powder and solvent for solution for injection (Cablivi®) SMC2266	Treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. Caplacizumab, compared with placebo, decreased the time to platelet count response and reduced the risk of thrombotic thrombocytopenic purpura recurrence in adults receiving plasma exchange and immunosuppression for aTTP	Available in line with national guidance	181	November 2020
Capsaicin (Qutenza®) (673/11)	Peripheral neuropathic pain	Formulary - HOSPITAL ONLY Chronis Pain specialist list	142 103	Oct/Nov 2014 Feb/Mar 2011
Capsaicin 179mg cutaneous patch (Qutenza®) 1140/16	Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.	Not available as not recommended for use in NHS Scotland	154	May 2016
Carbetocin 100 micrograms/mL solution for injection (Pabal®) SMC No (1)309/06	For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.	Not available as not recommended for use in NHS Scotland	167	April 2018
Carbetocin (Pabal®)	Prevention of uterine atony and excessive bleeding	Not recommended	60	2006
Carbomer gel (Liquivisc®)	Dry eye syndrome	Formulary	53	2005
carfilzomib 10mg, 30mg and 60mg powder for solution for infusion (Kyprolis®) SMC2484	In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not available as not recommended for use in NHS Scotland	189	May 2022

Carfilzomib 10mg, 30mg and 60mg powder for solution for infusion (Kyprolis®) SMC2290	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. SMC restriction: for patients who have received only one prior therapy. Carfilzomib in combination with lenalidomide and dexamethasone improved progression free survival and overall survival compared with lenalidomide and dexamethasone in adults with relapsed and / or refractory multiple myeloma who had received one to three prior therapies.	Available in line with national guidance	181	November 2020
Carfilzomib 10mg, 30mg, 60mg powder for solution for infusion (Kyprolis®) SMC No. (1242/17)	In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Carfilzomib in combination with dexamethasone, compared with another proteasome inhibitor in combination with dexamethasone, increased progression free survival in adults with relapsed or refractory multiple myeloma who had received between one and three previous lines of treatment.	Available in line with national guidance	163	Sep 2017
Carfilzomib 60mg powder for solution for infusion (Kyprolis®) (1171/16)	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy	Not available as not recommended for use in NHS Scotland.	157 159	Nov 2016 Feb 2017
Carglumic acid (Carbaglu®) (899/13)	Hyperammonaemia	HOSPITAL ONLY	131	Oct/Nov 2013
Carglumic acid (Carbaglu®)	N-acetylglutamate synthase deficiency		62	2006
Cariprazine 1.5mg, 3mg, 4.5mg and 6mg hard capsules (Reagila®) SMC2137	The treatment of schizophrenia in adult patients. SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	175	Aug 2019

Carmustine implant (Gliadel®) (215/05)	Malignant glioma	HOSPITAL ONLY (Neurosurgery)	108 Protocol 55	Aug 2011 2006
Caspofungin (Cancidas®) (551/09)	Empirical antifungal therapy in febrile neutropenic pts.	HOSPITAL ONLY	89 52 48	May 2009 2005
Caspofungin (Cancidas®) (552/09)	Invasive candidiasis in paediatric patients (12 months to 17 years)	HOSPITAL ONLY	89	May 2009
Caspofungin (Cancidas®)	Invasive candidiasis	HOSPITAL ONLY	37 35	2004
Caspofungin (Caspofungin®)	Invasive aspergillosis	Restricted use	25	2003
Catumaxomab (Removab®) (788/12)	Intraperitoneal treatment of malignant ascites	Not recommended	117	May/June 2012
Ceftazidime/avibactam 2g/0.5g powder for concentrate for solution for infusion (Zavicefta®) SMC No 1307/18	Treatment of the following infections in adults: • complicated intra-abdominal Infection (cIAI) • complicated urinary tract infection (cUTI), including pyelonephritis • hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • infections due to aerobic Gram-negative organisms in adult patients with limited treatment options	Not available as not recommended for use in NHS Scotland	167	April 2018

Ceftaroline fosamil 600 mg powder for concentrate for solution for infusion (Zinforo®) SMC No 1306/18	Treatment of • complicated skin and soft tissue infections in children from the age of 2 months • community-acquired pneumonia in children from the age of 2 months	Not available as not recommended for use in NHS Scotland	167	April 2018
Ceftaroline fosamil (Zinforo®) (830/12)	Treatment of complicated skin and soft tissue infections in adults	Non-formulary - alternatives preferred	124	Feb 2013
Ceftobiprole (Zevtera®) (943/14)	Indicated for the treatment of the following infections in adults: - Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP) - Community-acquired pneumonia (CAP)	Hospital Use Only Needs approved by Infectious Disease or Microbiology ALERT antibiotic	150	June 2015
Ceftolozane / tazobactam 1g/0.5g powder for concentrate for solution for infusion (Zerbaxa®) SMC 2256	In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.		178	Feb 2020
Ceftolozane-tazobactam 1g/0.5g powder for concentrate for solution for infusion (Zerbaxa®) SMC 1146/16	Treatment of following infections in adults: complicated intra-abdominal infections, acute pyelonephritis, complicated Urinary Tract Infections	Not available as not recommended for use in NHS Scotland	155	June 2016

Cefuroxime sodium (Aprokam®) (932/13)	Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by April 2017	133 159	Dec 13/Jan 14 Feb 2017
Celecoxib (Celebrex®) (410/07)	Ankylosing spondylitis	Not recommended	72	Sep 2007
cemiplimab concentrate for solution for infusion (Libtayo®) SMC2719	as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. In a phase III study, cemiplimab monotherapy resulted in a significant improvement in overall survival, compared with investigator's choice of chemotherapy.	Available in line with national guidance.		
Cemiplimab (Libtayo) SMC2584	As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 – awaiting publication	February 2024
Cemiplimab 350 mg concentrate for solution for infusion (Libtayo®) SMC2489	Is not recommended for use within nhsscotland. Indication under review: As monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)expressing PD-L1 (in ≥50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: • locally advanced NSCLC who are not candidates for definitive chemoradiation, or • metastatic NSCLC		189	May 2022

Cemiplimab 350mg concentrate for solution for infusion (Libtayo®) SMC 2216	As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. In a phase II study of cemiplimab in patients with metastatic or locally advanced CSCC the objective response rate was 44%. The base-case economic analysis submitted by the company assumed that patients were treated for a maximum of two years.	Available in line with local guidance for prescribing	179	Apr 2020
Cemiplimab (Libtayo) SMC2584	As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.	Available in line with national guidance	196	February / March 2024
cenobamate 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg film-coated tablets (Ontozry®) SMC2408	for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products. SMC restriction: in patients with drug-resistant epilepsy as a second-line adjunctive anti-seizure medicine, after the failure of the first adjunctive anti-seizure medicine In patients with uncontrolled focal seizures, despite treatment with anti-epileptic medicines, cenobamate was superior to placebo in terms of the proportion of patients experiencing a ≥50% reduction in focal seizure frequency.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	188	April 2022
Cenegermin 20mg/ml eye drops, solution (Oxervate®) SMC2124	Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.	Not available as not recommended for use in NHS Scotland	172	Dec 2018
Ceritinib 150mg hard capsules (Zykadia®) SMC No 1333/18	As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer.	Not available as not recommended by SMC	168	May 2018

Ceritinib 150mg hard capsules (Zykadia®) SMC No. 1097/15	Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Available in line with national guidance	153 157	Jan/Feb 2016 Nov 2016

Cerliponase alfa 150mg solution for infusion (Brineura®) SMC2290	For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. Key points: • CLN2 disease is a severe, neurodegenerative condition, diagnosed in childhood with devastating symptoms affecting multiple aspects of the child's life. There are no other medicines licensed for this condition. • A phase I/II study reported a clinically relevant treatment effect with cerliponase alfa, measured by the CLN2 motor/language (ML) scale at 48 weeks. This treatment effect was maintained through to week 96 in an extension study. Cerliponase alfa was also associated with significant treatment benefits when indirectly compared to standard of care from a historical control group. • The quality of life data are potentially difficult to interpret but can be considered positive. The stabilisation observed may be beneficial considering the decline in quality of life typically observed with CLN2 disease. • A model-based health economic evaluation suggests that cerliponase alfa is associated with a substantial gain in quality-adjusted life years compared to standard of care. However, the following issues add to the uncertainty of the results: assumptions regarding long term disease stabilisation; the distribution of patients in different starting health states; utility value estimates and the long time horizon. • Despite a Patient Access Scheme (PAS) that improves the cost-effectiveness of cerliponase alfa, the treatment's cost in relation to its health benefits remains high.	Included in ultra orphan pathway	181	November 2020
Certolizumab pegol 200mg solution for injection in pre-filled syringe and pen (Cimzia®) SMC2132	The treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	174	May 2019

Certolizumab pegol 200mg solution for injection (Comzie®) SMC 1155/16	Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDS	Not available as not recommended for use in NHS Scotland	155	June 2016
Certolizumab pegol (Cimzia®) (973/14)	Treatment of active psoriatic arthritis in adults	HOSPITAL ONLY (Rheumatology)	140	Jul/Aug 2014
Certolizumab pegol (Cimzia®) (960/14)	Treatment of adults with severe active axial spondyloarthritis	HOSPITAL ONLY	138	May/Jun 2014
Certolizumab pegol (Cimzia®) (590/09)	Severe, active rheumatoid arthritis	HOSPITAL ONLY	101 100 97	Oct/Nov 2010 Jun/Jul 2010
Cetuximab (Erbitux®) (1012/14)	EGFR - expressing RAS wild-type metastatic colorectal cancer	Awaiting specialist feedback	145	Feb 2015
Cetuximab (Erbitux®) (543/09)	EGFR-expressing KRAS wild-type metastatic colorectal cancer	HOSPITAL ONLY (Oncology)	127 116 95	May 2013 Apr/May 2012 Feb/Mar 2010
Cetuximab (Erbitux®) (279/06)	Locally advanced squamous cell cancer of the head and neck (SCCHN)	HOSPITAL ONLY (Oncology) - pending protocol update	116 87 60	Apr/May 2012 March 2009 2006
Cetuximab (Erbitux®)	Metastatic colorectal cancer	Not recommended	88 54 49	Apr 2009 2005
(Chenodeoxycholic acid Leadiant®) SMC2190	For the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.	Not available as not recommended for use in NHS Scotland	175	Aug 2019

Chlormethine hydrochloride (Ledaga) SMC 2318	For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. In a single-blind, randomised, phase II study, chlormethine gel was non-inferior to a compounded chlormethine ointment based on ≥50% improvement in Composite Assessment of Index Lesion Severity (CAILS) score confirmed after 4 weeks. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS / list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.	Available in line with national guidance	185	July 2021
Chloroprocaine hydrochloride 10mg/mL solution for injection (Ampres®) SMC2373	Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes. SMC restriction: for use in day-case anaesthetic pathways. In a small, single-centre, randomised, double blind study in patients undergoing knee arthroscopy, spinal anaesthesia with chloroprocaine injection compared with a hyperbaric formulation of an amide-type local anaesthetic agent was associated with a faster motor block recovery.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	187	Dec 2021
Cholecalciferol (InVita D3®) (1011/14)	Prevention and treatment of vitamin D deficiency.	GPs under recommendation of a paediatric specialist	144	Jan/Feb 2015
Choriogonadotropin alfa (Ovitrelle®)	Superovulation	HOSPITAL ONLY	62 59 58	2006
Choriogonadotropin alfa (Ovitrelle®)	Anovulation/oligo-ovulation	HOSPITAL ONLY	62 59 58	2006
Ciclesonide (Alvesco®) (412/07)	Asthma	Formulary	74 59 52	Nov 2007 2006 2005

Ciclosporin 0.9 mg/ml eye drops, solution in single-dose container (Cequa®) SMC2739	Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears. SMC restriction: severe keratitis in adult patients with Dry Eye Disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Ciclosporin 1mg/mL (0.1%) eye drops emulsion (Verkazia®) SMC2111	Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents	Not routinely available as local clinical experts do not wish to add to the formulary at this time or there is a local preference for alternative medicines	173	March 2019
Ciclosporin (Ikervis®) (1089/15)	For treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.	Hospital Only - Ophthalmology	152	Nov/Dec 2015
Cilostazol (Pletal®)	Intermittent claudication	Non-formulary	65 54 37	Jan 2007 2005 2004

Cinacalcet hydrochloride 1mg, 2.5mg and 5mg granules in capsules for opening (Mimpara®) SMC2275	Secondary hyperparathyroidism (HPT) • Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. • Treatment of secondary HPT in children aged 3 years and older with ESRD on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy Parathyroid carcinoma and primary HPT in adults • Reduction of hypercalcaemia in adult patients with: – parathyroid carcinoma. – primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated The holder of the marketing authorisation has not made a submission to SMC regarding this product in these indications. As a result we cannot recommend its use within NHSScotland.	For information only	180	Sept 2020
Cinacalcet (Mimpara®) (513/08)	Reduction of hypercalcaemia in patients with primary hyperparathyroidism (HPT)	Not recommended	83	Oct 2008
Cinacalcet (Mimpara®)	Secondary hyperparathyroidism in end-stage renal disease	HOSPITAL ONLY	66 57 50	Feb 2007 2006 2005
Cinacalcet (Mimpara®)	Hypercalcaemia in parathyroid carcinoma	Not recommended	58	2006
cipaglucosidase alfa powder for concentrate for solution for infusion (Pombiliti) SMC2606	as a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 – awaiting publication	February 2024

Ciprofloxacin ear drops solution, single dose container 2mg/mL (Cetraxal®) SMC No 1320/18	Treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. SMC restriction: when off-label or unlicensed ciprofloxacin formulations would otherwise be used.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	168	May 2018
Ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex®) SMC No (1256/17)	Treatment of the following infections in adults and children: Acute otitis media in patients with tympanostomy tubes (AOMT) Acute otitis externa. SMC Restriction: Treatment of acute otitis media in patients with tympanostomy tubes (AOMT).	Available in line with national guidance	163	Sep 2017
Cladribine tablet (Mavenclad®) SMC2751	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features. SMC restriction: for use in patients with active relapsing-remitting multiple sclerosis (RRMS)			
Cladribine 10mg tablet (Mavenclad®) SMC No 1300/18	Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. SMC restrictions: • Patients with rapidly evolving severe relapsing-remitting MS: patients with two or more relapses in the prior year whether on treatment or not, and at least one T1 gadolinium-enhancing lesion. • Patients with sub-optimal therapy relapsing-remitting MS: patients with one or more relapses in the previous year while on disease modifying therapy, and at least one T1 gadolinium-enhancing lesion or nine T2 lesions.	Available in line with local guidance for prescribing	167	April 2018
Cladribine (Litak®) (537/09)	Hairy cell carcinoma	HOSPITAL ONLY (Oncology) Formulary - pending protocol	116 87	Apr/May 2012 Mar 2009

Clindamycin 1% / tretinoin 0.025% gel (Treclin®) (1010/14)	For the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.	Formulary - GPs where the combination of the two products is clinically indicated	144	Jan/Feb 2015
Clarithromycin granules (ClaroSip®)	Acute and chronic infections	Not recommended	55	2006
Clindamycin/benzoyl peroxide (Duac®)	Mild to moderate acne vulgaris		39 38	2004
Clobetasol propionate 0.05% shampoo (Etrivex®) (434/07)	Scalp psoriasis in adults	Formulary	82 77 151	Aug/Sep 2008 Mar 2008 Sep/Oct 2015
Clobetasol propionate foam (Clarelux®)	Scalp dermatoses	Formulary	60 151	2006 Sep/Oct2015
Clofarabine (Evoltra®)	Acute lymphoblastic leukaemia (ALL) in paediatric patients		65	Jan 2007
Clopidogrel (Plavix®)	STEMI in combination with low dose aspirin		96 74 72	Apr/May 2010 Nov 2007 Sep 2007
Clopidogrel (Plavix®)	Acute coronary syndrome (NSTEMI)		96 70 37	Apr/May 2010 Jun 2007 2004
Clostridium botulinum neurotoxin type A powder for solution for injection (Xeomin®) SMC2680	Focal spasticity of the lower limb affecting the ankle joint.	Not recommended for use in NHS Scotland	198 not yet published	

Clostridium botulinum neurotoxin type A 50, 100, and 200 units powder for solution for injection (Xeomin®) SMC2212	For the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	178	Feb 2020
Clostridium botulinum type A toxin-haemagglutinin complex 300 and 500 units (Dysport®) SMC No 1321/18	Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.	Not available as not recommended in NHS Scotland	168	May 2018
Clostridium botulinum neurotoxin type A (Xeomin®) (464/08)	Blepharospasm and cervical dystonia	HOSPITAL ONLY	81 80	Jul 2008 Jun 2008
Clostridium botulinum type A toxin (Dysport®) (353/07)	Focal spasticity	Non-formulary - alternatives preferred	124 67	Feb 2013 Mar 2007
Cobicistat (Tybost®) (933/13)	HIV-1	Not recommended	138	May/Jun 2014
Cobimetinib 20mg film-coated tablets (Cotellic®) (1191/16)	In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not available as not recommended for use in NHS Scotland.	157	Nov 2016
Co-careldopa (levodopa 20mg/mL and carbidopa monohydrate 5mg/mL) intestinal gel (Duodopa®) SMC No. 316/06	Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines (Link to Formulary)	153 156	Jan/Feb 2016 Sep 2016
Co-careldopa intestinal gel infusion (Duodopa®)	Advanced Parkinson's disease	Not recommended	62	2006

Colecalciferol (Desunin 800 IU®) (840/13)	Prevention and treatment of Vitamin D deficiency	Vitamin D deficiency Formulary - restricted to treatment of vitamin D deficiency. Osteoporosis Formulary - restricted to patients in whom a combined vitamin D and calcium supplement is unsuitable.	126 Protocol 124	Apr 2013 Feb 2013
Colecalciferol (Fultium-D3®) (801/12)	Prevention and treatment of Vitamin D deficiency	Non-formulary - alternatives preferred	124 121 120	Feb 2013 Nov 2012 Oct 2012
Colesevelam (Cholestagel®) (690/11)	Hypercholesterolaemia	Not recommended	103 77	Feb/Mar 2011 Mar 2008
Colestilan (BlindRen®) (939/14)	Chronic kidney disease (CKD)	Discontinued	140	Jul/Aug 2014
Colestilan (BlindRen®) (939/14)	Hyperphosphataemia in adults with CKD	Discontinued	146 135	Feb 2015 Feb/Mar 2014
Colistimethate sodium dry powder for inhalation, hard capsules, 1.66 million units/capsule (Colobreathe®) NICE TA 276; Mar 13	Chronic pseudomonas lung infection in cystic fibrosis patients	GPs under the direction of secondary care	135 129	Feb/Mar 2014 Aug/Sep 2013
Collagenase clostridium histolyticum (Xiapex) (1059/15)	Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.	Not Recommended	148	May 2015

Collagenase clostridium histolyticum (Xiapex®) (715/11)	Dupuytren's contracture in adult patients with a palpable cord	HOSPITAL ONLY (Plastic Surgery Clinic)	123 119 117 109	Jan 2013 Aug/Sep 2012 May/Jun 2012 Sep 2011
Conestat alfa 2,100 units powder (and solvent) for solution for injection (Ruconest®) SMC No 745/11	For treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. Conestat alfa was associated with a significantly shorter time to relief from symptoms of HAE attack compared with placebo during controlled phase III studies.	Available in line with local guidance for prescribing.	111 170	Nov 2011 Sep 2018
Conjugated estrogen tablets (Premarin®) (413/07)	HRT	Non-formulary	74	Nov 2007
Conjugated oestrogen/ medroxyprogesterone (Premique® Low Dose)	HRT	Non-formulary	46	2004
Corifolitropin alfa (Elonva®)	Controlled ovarian stimulation (COS)	Not recommended	97	Jun/Jul 2010
Creon® micro	Pancreatic exocrine insufficiency		95 47	Feb/Mar 2010 2004
Crizanlizumab 10mg/ml concentrate for solution for infusion (Adakveo®)SMC2438	For the prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxycarbamide or as monotherapy in patients for whom hydroxycarbamide is inappropriate or inadequate.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
crizotinib hard capsules (Xalkori®) SMC2621	As monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with:	Not available as not recommended for use in NHS Scotland	195	December 2023

Crizotinib 200mg and 250mg hard capsules (Xalkori®) SMC No 1329/18	Treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).	Available in line with national guidance	169	July 2018
Crizotinib (Xalkori®)1152/16	First line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non small cell lung cancer.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	156	Sep 2016
Crizotinib (Xalkori®) (865/13)	(ALK)-positive advanced non-small cell lung cancer (NSCLC)	HOSPITAL ONLY - Oncology	131 127	Oct /Nov 2013 May 2013
Crovalimab solution for injection/infusion (Piasky®) SMC2728	As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): • In patients with haemolysis with clinical symptom(s) indicative of high disease activity. • In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months. SMC restriction: under the advice of the national PNH service	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Cytarabine liposomal suspension (Depocyte®) (164/05)	Lymphomatous meningitis	Not recommended	72 50	Sep 2007 2005

Updated: 9th June 2025

Back to top Back to homepage